Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Decreases By 25.1%

Achilles Therapeutics plc (NASDAQ:ACHL) saw a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 159,300 shares, a drop of 25.1% from the October 15th total of 212,600 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily trading volume, of 642,000 shares, the short-interest ratio is currently 0.2 days.

Achilles Therapeutics Price Performance

Shares of ACHL stock opened at $1.07 on Friday. The stock has a market capitalization of $43.97 million, a price-to-earnings ratio of -0.64 and a beta of 1.35. The company’s fifty day simple moving average is $0.94 and its two-hundred day simple moving average is $0.87. Achilles Therapeutics has a 1 year low of $0.63 and a 1 year high of $1.76.

Achilles Therapeutics (NASDAQ:ACHL) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.41). Equities research analysts anticipate that Achilles Therapeutics will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. BML Capital Management LLC grew its position in shares of Achilles Therapeutics by 555.8% during the 3rd quarter. BML Capital Management LLC now owns 4,100,002 shares of the company’s stock valued at $4,182,000 after purchasing an additional 3,474,828 shares in the last quarter. Ikarian Capital LLC bought a new position in Achilles Therapeutics in the 1st quarter worth about $1,804,000. StemPoint Capital LP bought a new position in Achilles Therapeutics in the 1st quarter worth about $1,732,000. Acadian Asset Management LLC purchased a new stake in shares of Achilles Therapeutics in the 1st quarter valued at about $350,000. Finally, XTX Topco Ltd boosted its position in shares of Achilles Therapeutics by 239.4% during the 2nd quarter. XTX Topco Ltd now owns 51,660 shares of the company’s stock valued at $42,000 after acquiring an additional 36,441 shares during the last quarter. Hedge funds and other institutional investors own 56.38% of the company’s stock.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.